An alternative approach to combination vaccines: Intradermal administration of isolated components for control of anthrax, botulism, plague and staphylococcal toxic shock

Journal of Immune Based Therapies and Vaccines

Volumn 6, Issue , 2008, Pages

  Morefield, Garry L ^a   Tammariello, Ralph F ^a   Purcell, Bret K ^a   Worsham, Patricia L ^a   Chapman, Jennifer ^a   Smith, Leonard A ^a   Alarcon, Jason B ^b   Mikszta, John A ^b   Ulrich, Robert G ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Becton Dickinson Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTHRAX VACCINE; BACTERIAL VACCINE; BOTULINUM TOXIN A; HYBRID PROTEIN; PLAGUE VACCINE; RECOMBINANT ANTIGEN; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; STAPHYLOCOCCUS ENTEROTOXIN B; STEBVAX; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHRAX; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; BACILLUS ANTHRACIS; BOTULISM; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSPORT; LYMPHATIC DRAINAGE; NONHUMAN; PLAGUE; SEPTIC SHOCK; STREPTOCOCCUS INFECTION;

EID: 52649096488     PISSN: None     EISSN: 14768518     Source Type: Journal    
DOI: 10.1186/1476-8518-6-5     Document Type: Article

References (26)

1. Hilton S Petticrew M Hunt K: Combined vaccines are like a sudden onslaught to the body's immune system: Parental concerns about vaccine 'overload' and 'immune-vulnerability.' Vaccine 2006, 24:4321-4327. 10.1016/j.vaccine.2006.03.003 16581162
2. Capiau C Poolman J Hoet B Bogaerts H Andre F: Development and clinical testing of multivalent vaccines based on a diphtheria-tetanus-acellular pertussis vaccine: Difficulties encountered and lessons learned. Vaccine 2003, 21:2273-2287. 10.1016/S0264-410X(03)00107-5 12744858
3. Laurent; PE Bonnet S Alchas P Regolini P Mikszta JA Pettis R Harvey NG: Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007, 25:8833-8842. 10.1016/j.vaccine.2007.10.020 18023942
4. Redfield RR Innis BL Scott RM Cannon HG Bancroft WH: Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. J Am Med Assoc 1985, 254:3203-3206. 10.1001/ jama.254.22.3203
5. Belshe RB Newman FK Cannon J Duane C Treanor J Van Hoecke B Howe J Dubin G: Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004, 351;2286-2294. 10.1056/NEJMoa043555 15525713
6. Klimpel KR Arora N Leppla SH: Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol Microbiol 1994. 13:1093-1100. 10.1111/ j.1365-2958.1994.tb00500.x 7854123
7. Vitale G Pellizzari R Recchi C Napolitani G Mock M Montecucco C: Anthrax lethal factor cleaves the N-terminus of MAPKKS and induces tyrosine/ threonine phosphorylation of MAPKS in cultured macrophages. J Appl Microbiol 1999, 87:288. 10.1046/j.1365-2672.1999.00893.x 10475970
8. Leppla SH; Anthrax toxin edema factor: A bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci USA 1982, 79:3162-3166. 346374 6285339 10.1073/pnas.79.10.3162
9. Drum CL Yan SZ Sarac R Mabuchi Y Beckingham K Bohm A Grabarek Z Tang WJ; An extended conformation of calmodulin induces interactions between the structural domains of adenylyl cyclase from Bacillus anthracis to promote catalysis. J Biol Chem 2000, 275:36334-36340. 10.1074/ jbc.M004778200 10926933
10. Ivins BE Pitt ML Fellows PF Farchaus JW Benner GE Waag DM Little SF Anderson GW Gibbs PH Friedlander AM: Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 1998, 16:1141-1148. 10.1016/ S0264-410X(98)80112-6 9682372
11. Fellows PF Linscott MK Ivins BE Pitt ML Rossi CA Gibbs PH Friedlander AM: Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 2001, 19:3241-3247. 10.1016/ S0264-410X(01)00021-4 11312020
12. Habermann E Dreyer H: Clostridial neurotoxins: handling and action at the cellular and molecular level. Curr Top Microbiol Immunol 1986, 129:93-179. 3533452
13. Boles J West M Montgomery V Tammariello R Pitt ML Gibbs P Smith L LeClaire RD: Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. Toxicon 2006, 47:877-884. 10.1016/j.toxicon.2006.02.013 16730042
14. Fraser J Arcus V Kong P Baker E Proft T: Superantigens-powerful modifiers of the immune system. Mol Med Today 2000, 6:125-132. 10.1016/ S1357-4310(99)01657-3 10689316
15. Ulrich RG Bavari S Olson MA: Bacterial superantigens in human disease: structure, function and diversity. Trends Microbiol 1995, 3:463-468. 10.1016/S0966-842X(00)89011-3 8800837
16. Ulrich RG Bavari S Olson MA; Development of engineered vaccines effective against structurally related bacterial superantigens. Vaccine 1998, 16:1857-1864. 10.1016/S0264-410X(98)00176-5 9795392
17. Boles JW Pitt ML LeClaire RD Gibbs PH Torres E Dyas B Ulrich RG Bavari S: Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. Clin Immunol 2003, 108:51-59. 10.1016/S1521-6616(03)00066-4 12865071
18. Williamson; ED Eley SM Stagg AJ Green M Russell P Titball RW: A single dose sub-unit vaccine protects against pneumonic plague. Vaccine 2000, 19:566-571. 10.1016/S0264-410X(00)00159-6 11027822
19. Heath DG Anderson GW Jr Mauro JM Welkos SL Andrews GP Adamovicz J Friedlander AM: Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 1998, 16:1131-1137. 10.1016/S0264-410X(98)80110-2 9682370
20. Dean CH Alarcon JB Waterston AM Draper K Early R Guirakhoo F Monath TP Mikszta JA: Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax-JE) in non-human primates. Hum Vaccin 2005, 1(3):106-111. 17012854
21. Prophet EB Mills B Arrington JB Sobin LH: Laboratory Methods for Histotechnology Armed Forces Institute of Pathology, Washington, D.C. 1992:25-29.
22. S5aikh KU Kissner TL Dyas B Tropea JE Waugh DS Ulrich RG: Human cytolytic T cell recognition of Yersinia pestis virulence proteins that target innate immune responses. J Infect Dis 2006. 194:1753-1760. 10.1086/509507 17109349
23. Zhou F Santoli J Messonnier ML Yusuf HR Shefer A Chu SY Rodewald L Harpaz R: Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001. Arch Pediatr Adolesc Med 2005, 159:1136-1144. 10.1001/archpedi.159.12.1136 16330737
24. Mikszta JA Sullivan VJ Dean C Waterston AM Alarcon JB Dekker JP 3rd Brittingham JM Huang J Hwang CR Ferriter M Jiang G Mar K Saikh KU Stiles BG Roy CJ Ulrich RG Harvey NG: Protective immunization against inhalational anthrax: A comparison of minimally invasive delivery platforms. J Infect Dis 2005, 191:278-288. 10.1086/426865 15609239
25. Mikszta JA Dekker JP 3rd Harvey NG Dean CH Brittingham JM Huang J Sullivan VJ Dyas B Roy CJ Ulrich RG: Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect Immun 2006, 74:6806-6810. 1698069 17030580 10.1128/IAI.01210-06
26. Alarcon JB Waterston Hartley A Harvey NG Mikszta JA: Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines. Clin Vacc Immunol 2007, 14:375-381. 10.1128/ CVI.00387-06